Industry
Biotechnology
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
Loading...
Open
11.35
Mkt cap
483M
Volume
215K
High
11.57
P/E Ratio
-3.13
52-wk high
16.88
Low
11.02
Div yield
N/A
52-wk low
7.21
Portfolio Pulse from Benzinga Newsdesk
October 28, 2024 | 10:33 am
Portfolio Pulse from Benzinga Newsdesk
October 07, 2024 | 10:58 am
Portfolio Pulse from Benzinga Newsdesk
October 04, 2024 | 4:32 pm
Portfolio Pulse from Benzinga Newsdesk
September 30, 2024 | 10:43 am
Portfolio Pulse from Benzinga Newsdesk
September 27, 2024 | 3:01 pm
Portfolio Pulse from Benzinga Newsdesk
September 27, 2024 | 1:39 pm
Portfolio Pulse from Benzinga Newsdesk
September 10, 2024 | 10:31 am
Portfolio Pulse from Benzinga Newsdesk
September 09, 2024 | 5:16 pm
Portfolio Pulse from Benzinga Newsdesk
September 06, 2024 | 11:39 am
Portfolio Pulse from Nabaparna Bhattacharya
September 06, 2024 | 10:35 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.